• Learning Objective 1: To gain familiarity with the multiple clinical and etiological subsets of therapy-related myeloid neoplasms, and the ramifications for therapy.
  • Learning Objective 2: To recognize the emerging risk factors for therapy-related myeloid neoplasms, and their potential relevance to other secondary malignant neoplasms in children.
  • Learning Objective 3: To appreciate the history and role of the University of Chicago and Dr. Charles Rubin in characterizing and defining therapy-related myeloid neoplasms.
Session date: 
05/04/2023 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michelle LeBeau, PhD